DNIB0600A: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 18 evaluable patients with non-squamous NSCLC or platinum-resistant ovarian cancer showed that 1.8-2.8 mg/kg doses of IV DNIB0600A given every 3 w...